Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cell secretome
- Development stage
- Phase 3
- Lead developer
- Kala Bio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies
- Administration
- Ophthalmic, Intraarticular, Topical, Intravenous, Intradermal, Subcutaneous, Intrathecal, Intranasal, Inhalation, Intracavernosal, Intratumoral, Intrauterine
01
Overview
Mesenchymal stem cell (MSC) secretome, often referred to as Secretome-MSCs in clinical trials, is a cell-free therapeutic product consisting of the complete set of bioactive factors secreted by MSCs, including cytokines, chemokines, growth factors, and extracellular vesicles (exosomes and microvesicles). It is being developed as a safer and more easily standardized alternative to live MSC transplantation. The secretome mediates tissue repair and immunomodulation by suppressing inflammatory responses and reducing oxidative stress. Clinical research is currently evaluating its efficacy in treating severe COVID-19 to prevent cytokine storms and in managing rheumatoid arthritis. Preclinical evidence also suggests potential applications in treating opioid addiction by mitigating neuroinflammation and brain oxidative stress.
- Other names
- MSC secretomeMSC-derived secretomemesenchymal stem cell-derived secretomeMSC conditioned mediumMSC-CM
Beyond the preview
Go deeper on mesenchymal stem cell secretome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cell secretome.